Shareholders approve Humacyte, SPAC merger; deal to close this week

Medtech firm Bioventus acquires California medical device company in deal worth up to $110M


DURHAM – Shareholders of Alpha Healthcare Acquisition Corp., a special purpose acquisition company, have approved the previously announced business combination with Durham-headquartered Humacyte, the company announced today in a statement.

The deal was originally announced in February and included $175 million in capital.

According to the company, its shareholders approved the proposal with 99.5% votes in favor of the approximately 61.6% of shareholder votes cast at the meeting.

The deal is expected to close on August 26, the company stated.  Following closing, the combined company will operate as Humacyte, Inc., and starting on or about August 27, the company will sell shares of common stock and warrants under the ticker symbols “HUMA” and “HUMAW,” the statement noted.

The company received startup support from the North Carolina Biotechnology Center more than 15 years ago.  WRAL TechWire profiled the growth of the company in a February story.

A blooming success: The rise of Humacyte from humble beginnings to $1.1B valuation

The company expanded its collaboration with one of the financial backers of its business combination plan in June.





Source link

About the Author

Anthony Barnett
Anthony is the author of the Science & Technology section of ANH.